A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6119-6127

  Ghosh, Subrata K ^a   Kim, Pilhan ^b   Zhang, Xiao An ^c   Yun, Seok Hyun ^b   Moore, Anna ^a   Lippard, Stephen J ^c   Medarova, Zdravka ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FLUID; CANCER DIAGNOSIS; CANCER GROWTH; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; EARLY DETECTION OF CANCER; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; PYRIDINES; TUMOR MARKERS, BIOLOGICAL; ZINC;

EID: 77955407606     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1008     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Fitzsimons NJ, Sun L, Moul JW. Medical technologies for the diagnosis of prostate cancer. Expert Rev Med Devices 2007;4:227-39. (Pubitemid 46522770)
3. Nash AF, Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocr Relat Cancer 2000;7:37-51. (Pubitemid 30305870)
4. Franklin RB, Feng P, Milon B, et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer 2005;4:32.
5. Mawson CA, Fischer MI. The occurrence of zinc in the human prostate gland. Can J Med Sci 1952;30:336-9.
6. Costello LC, Franklin RB. Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem. Prostate Cancer Prostatic Dis 2009;12:17-24.
7. Zaichick VY, Sviridova TV, Zaichick SV. Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol 1996;28:687-94.
8. Cortesi M, Chechik R, Breskin A, et al. Evaluating the cancer detection and grading potential of prostatic-zinc imaging: a simulation study. Phys Med Biol 2009;54:781-96.
9. Cortesi M, Fridman E, Volkov A, et al. Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needlebiopsy study. Prostate 2008;68:994-1006. (Pubitemid 351794164)
10. Zhang XA, Hayes D, Smith SJ, Friedle S, Lippard SJ. New strategy for quantifying biological zinc by a modified zinpyr fluorescence sensor. J Am Chem Soc 2008;130:15788-9.
11. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010;70:2595-603.
12. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
13. Bai A, Higham E, Eisen HN, Wittrup KD, Chen J. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A 2008;105:13003-8.
14. Niu Y, Altuwaijri S, Yeh S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A 2008;105:12188-93.
15. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-4. (Pubitemid 46606879)
16. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49.
17. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8.
18. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
19. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
20. Corbacho AM, Valacchi G, Kubala L, et al. Tissue-specific gene expression of prolactin receptor in the acute-phase response induced by lipopolysaccharides. Am J Physiol Endocrinol Metab 2004;287:E750-7.
21. Kim P, Puoris'haag M, Cote D, Lin CP, Yun SH. In vivo confocal and multiphoton microendoscopy. J Biomed Opt 2008;13:010501.
22. Costello LC, Liu Y, Zou J, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem 1999;274:17499-504. (Pubitemid 129519095)
23. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 2009;115:2863-71.